Melanotan I (afamelanotide) is a selective MC1R (melanocortin-1 receptor) agonist and the linear analog of alpha-MSH — distinct from Melanotan II in both structure and receptor selectivity profile. While Melanotan II is cyclic and non-selectively activates MC1R, MC3R, MC4R, and MC5R (producing tanning, libido, appetite, and other effects through multiple receptor subtypes), Melanotan I is linear, longer-acting, and selectively activates MC1R with minimal MC3R/MC4R activity — providing UV-independent tanning through the melanogenesis pathway without the sexual arousal, appetite suppression, nausea, or cardiovascular effects attributable to MC4R/MC3R activation in Melanotan II.

MC1R is the key receptor governing skin pigmentation. MC1R activation triggers cAMP signaling in melanocytes, which drives the shift from pheomelanin (yellow/red, photoprotective) to eumelanin (brown/black, highly photoprotective) synthesis — increasing the concentration of the more UV-absorbing melanin type and darkening skin pigmentation. This eumelanin shift provides actual photoprotection: eumelanin efficiently dissipates UV photon energy as heat rather than allowing it to cause DNA damage, which is why MC1R activation (through sun exposure or afamelanotide) constitutes genuine photoprotection rather than simply cosmetic tanning.

Afamelanotide is an FDA-approved pharmaceutical in Europe (Scenesse, Clinuvel Pharmaceuticals) for the rare photosensitivity disorder erythropoietic protoporphyria (EPP) — where solar-induced pain severely limits sun exposure and quality of life. The approval was based on rigorous Phase 3 randomized controlled trials demonstrating significantly increased pain-free sun exposure time in EPP patients. It has also been studied in solar urticaria, vitiligo (to stimulate repigmentation in affected areas), and skin cancer prevention in high-risk populations (organ transplant recipients on immunosuppression with elevated squamous cell carcinoma risk).

The photoprotection mechanism of Melanotan I makes it relevant for populations with high UV exposure risk: fair-skinned individuals with low baseline melanin, those with personal or family history of melanoma, outdoor workers, and people in high-altitude or high-UV environments. The SC-16 implant form of afamelanotide (used in EPP clinical trials) provides slow-release over 2 months from a single implant; the injectable peptide form provides shorter-duration tanning effects from weekly or bi-weekly injections.

The superior selectivity of Melanotan I for MC1R with reduced MC4R activity makes it the preferred compound for users seeking UV-independent tanning or photoprotective pigmentation without the sexual, appetite, or nausea side effects of non-selective MT-II. The absence of MC4R-mediated libido effects makes it appropriate for female users who experienced unwanted sexual side effects with Melanotan II.

Protocol: 1–2mg/day SC injection for 5–7 days for initial tanning, maintenance 1–2mg twice weekly.